It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Owing to its ability to induce cellular senescence, inhibit PCNA, and arrest cell division cycle by negatively regulating CDKs as well as being a primary target of p53, p21 is traditionally considered a tumor suppressor. Nonetheless, several reports in recent years demonstrated its pro-oncogenic activities such as apoptosis inhibition by cytosolic p21, stimulation of cell motility, and promoting assembly of cyclin D-CDK4/6 complex. These opposing effects of p21 on cell proliferation, supported by the observations of its inconsistent expression in human cancers, led to the emergence of the concept of “antagonistic duality” of p21 in cancer progression. Here we demonstrate that p21 negatively regulates basal autophagy at physiological concentration. Akt activation, upon p21 attenuation, driven ROS accumulation appears to be the major underlying mechanism in p21-mediated modulation of autophagy. We also find p21, as a physiological inhibitor of autophagy, to have oncogenic activity during early events of tumor development while its inhibition favors survival and growth of cancer cells in the established tumor. Our data, thereby, reveal the potential role of autophagy in antagonistic functional duality of p21 in cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 CSIR-Central Drug Research Institute, Cancer Biology Division, Lucknow, India (GRID:grid.418363.b) (ISNI:0000 0004 0506 6543)
2 CSIR-Central Drug Research Institute, Cancer Biology Division, Lucknow, India (GRID:grid.418363.b) (ISNI:0000 0004 0506 6543); Academy of Scientific and Innovative Research, Ghaziabad, India (GRID:grid.469887.c) (ISNI:0000 0004 7744 2771)
3 CSIR-Central Drug Research Institute, Electron Microscopy Unit, Lucknow, India (GRID:grid.418363.b) (ISNI:0000 0004 0506 6543)
4 Academy of Scientific and Innovative Research, Ghaziabad, India (GRID:grid.469887.c) (ISNI:0000 0004 7744 2771); CSIR-Central Drug Research Institute, Electron Microscopy Unit, Lucknow, India (GRID:grid.418363.b) (ISNI:0000 0004 0506 6543)